Medeon

SEQ_NO	1	Date of announcement	2026/03/23	Time of announcement	14:35:29
Subject	The Company has been required by TPEx to announce the financial data according to the regulations.
Date of events	2026/03/23	To which item it meets	paragraph 53
Statement	1.Date of occurrence of the event: 2026/03/23 2.Cause of occurrence:Announced as required by the TPEx 3.Financial and business information: Unit: (NT$million) (1) Monthly Feb 2026 Feb 2025 YoY Change % ————————————————————————– Sales revenue 47.9 36.2 32.3% (Revenue increased) Loss before income tax (39.4) (63.8) 38.2% (Losses reduced) Net Loss attributable to Owners of the parent (35.5) (59.4) 40.2% (Losses reduced) EPS (NT$) (0.4) (0.6) 43.1% (Losses reduced) ========================================================================== (2)Quarterly Q4 2025 Q4 2024 YoY Change % ————————————————————————– Sales revenue 114.9 77.3 48.5% (Revenue increased) Loss before income tax (154.7) (225.9) 31.5% (Losses reduced) Net Loss attributable to Owners of the parent (137.1) (208.8) 34.3% (Losses reduced) EPS (NT$) (1.5) (2.3) 34.5% (Losses reduced) ========================================================================== (3)Cumulative for the last four seasons Latest 4 quarters accumulation (Q1 2025 to Q4 2025) ————————————————————————– Revenue 419.4 Loss before income tax (719.7) Net Loss attributable to Owners of the parent (668.1) EPS (NT$) (7.2) ========================================================================== 4.Any material information that needs to be specified according to Article 4 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: Medeon has disclosed material information titled ‘Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance’ in accordance with Article 53 over the past six business days. 5.Any material information in a press conference listed under Article 11 of Taipei Exchange Procedures for Verification and Disclosure of Material Information of Companies with TPEx Listed Securities: Medeon has not held any press conferences to explain material information in the past six business days. 6.Any other matters that need to be specified: (1)The aforementioned financial information for February 2026 and its YOY comparison consists in the consolidated reviewed amounts prepared by the Company adopting the IFRS, and has not been audited (reviewed) by CPA. This information is provided for investors’ reference only. (2)The information for the latest quarter (Q4 2025) refers to single quarter amounts, not cumulative amounts from the latest financial reports, and are consolidated amounts prepared under the IFRS, which have been audited (reviewed) by CPA. This information is provided for investors’ reference only. (3)The information accumulated over the last 4 quarters consists in the consolidated amounts from Q1 2025 to Q4 2025 prepared by the Company adopting the IFRS, and has been audited (reviewed) by CPA. This information is provided for investors’ reference only.